From the *Department of Nuclear Medicine, University Hospital Bonn, Bonn; and †Private Office for Urology, Bonn, Germany.
Clin Nucl Med. 2016 Nov;41(11):894-895. doi: 10.1097/RLU.0000000000001358.
An 81-year-old castrate-resistant prostate cancer man with multiple lymph node, bone, and hepatic metastases received four cycles of Lu-PSMA-617 treatments at our department from May to December 2015. All of his liver metastases showed PSMA expression in Ga-PSMA PET performed before the first cycle. Under this therapy, all of the metastases showed significant regression in size and PSMA expression over time.
一位 81 岁去势抵抗性前列腺癌男性患者，多发淋巴结、骨和肝转移，曾于 2015 年 5 月至 12 月在我科接受了四个周期的 Lu-PSMA-617 治疗。他所有的肝转移病灶在第一个周期前进行的 Ga-PSMA PET 中均显示 PSMA 表达。在这种治疗下，随着时间的推移，所有转移病灶的大小和 PSMA 表达均显著消退。
